# HPV type 6/11/16/18/31/33/45/52/58 L1 protein

## Gardasil 9 (HPV, Government) inj 0.5mL/dose

| TAH Drug Code      | [IGAR0](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IGAR0)                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For 9 to 45 years old people to prevent diseases caused by human papillomavirus (HPV) (cervical cancer, genital warts & precancerous or dysplastic lesions) Precancerous lesions and cancers of the cervix, vulva, vagina and anus caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. Genital warts (condyloma acuminatum) caused by HPV types 6 and 11.                                                               |
| Dosing             | Intramuscular injection only, dosage: 0.5 mL per dose, in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. - Ages 9 to 14: 2 doses at 0 and 6-12 months* - Ages 9 to 14: 3 doses at 0, 2, and 6 months - Ages 15 to 45: 3 doses at 0, 2, and 6 months *If the second dose is administered less than 5 months after the first, a third dose is needed at least 4 months after the second. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity reactions following a dose of human papillomavirus recombinant vaccine quadrivalent (Types 6, 11, 16, 18) or human papillomavirus 9-valent vaccine, recombinant. Severe allergic reactions to yeast.                                                                                                                                                                                                         |
| Adverse Effects    | Common: Erythema at injection site (Boys, 24.9%; girls and women, 34-42.3%; boys and men, 20.7%), Injection site pain (Boys, 71.5%; girls and women, 89.3-90.3%; boys and men, 63.4%), Swelling at injection site (Boys, 26.9%; girls and women, 40-49%; boys and men, 20.2%), Headache (7.3-14.6%) Serious: Syncope (0.2%)                                                                                                   |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information)                                                                                                                                                                                                                                                                                                                    |

## Gardasil 9 (HPV, Taipei) inj 0.5mL/dose

| TAH Drug Code      | [IGAR2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IGAR2)                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For 9 to 45 years old people to prevent diseases caused by human papillomavirus (HPV) (cervical cancer, genital warts & precancerous or dysplastic lesions) Precancerous lesions and cancers of the cervix, vulva, vagina and anus caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. Genital warts (condyloma acuminatum) caused by HPV types 6 and 11.                                                               |
| Dosing             | Intramuscular injection only, dosage: 0.5 mL per dose, in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. - Ages 9 to 14: 2 doses at 0 and 6-12 months* - Ages 9 to 14: 3 doses at 0, 2, and 6 months - Ages 15 to 45: 3 doses at 0, 2, and 6 months *If the second dose is administered less than 5 months after the first, a third dose is needed at least 4 months after the second. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity reactions following a dose of human papillomavirus recombinant vaccine quadrivalent (Types 6, 11, 16, 18) or human papillomavirus 9-valent vaccine, recombinant. Severe allergic reactions to yeast.                                                                                                                                                                                                         |
| Adverse Effects    | Common: Erythema at injection site (Boys, 24.9%; girls and women, 34-42.3%; boys and men, 20.7%), Injection site pain (Boys, 71.5%; girls and women, 89.3-90.3%; boys and men, 63.4%), Swelling at injection site (Boys, 26.9%; girls and women, 40-49%; boys and men, 20.2%), Headache (7.3-14.6%). Serious: Syncope (0.2%)                                                                                                  |
| Pregnancy          | No (Limited) Human Data â€“ Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                    |
| More Info          | [UpToDate](https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information)                                                                                                                                                                                                                                                                                                                    |

## Gardasil 9 inj 0.5mL/dose

| TAH Drug Code      | [IGAR9](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IGAR9)                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For 9 to 45 years old people to prevent diseases caused by human papillomavirus (HPV) (cervical cancer, genital warts & precancerous or dysplastic lesions) Precancerous lesions and cancers of the cervix, vulva, vagina and anus caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. Genital warts (condyloma acuminatum) caused by HPV types 6 and 11.                                                               |
| Dosing             | Intramuscular injection only, dosage: 0.5 mL per dose, in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. - Ages 9 to 14: 2 doses at 0 and 6-12 months* - Ages 9 to 14: 3 doses at 0, 2, and 6 months - Ages 15 to 45: 3 doses at 0, 2, and 6 months *If the second dose is administered less than 5 months after the first, a third dose is needed at least 4 months after the second. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity reactions following a dose of human papillomavirus recombinant vaccine quadrivalent (Types 6, 11, 16, 18) or human papillomavirus 9-valent vaccine, recombinant. Severe allergic reactions to yeast.                                                                                                                                                                                                         |
| Adverse Effects    | Common: Erythema at injection site (Boys, 24.9%; girls and women, 34-42.3%; boys and men, 20.7%), Injection site pain (Boys, 71.5%; girls and women, 89.3-90.3%; boys and men, 63.4%), Swelling at injection site (Boys, 26.9%; girls and women, 40-49%; boys and men, 20.2%), Headache (7.3-14.6%). . Serious: Syncope (0.2%)                                                                                                |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information)                                                                                                                                                                                                                                                                                                                    |

